Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives.
about
Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinomaAntiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.Eg5 Overexpression Is Predictive of Poor Prognosis in Hepatocellular Carcinoma Patients.AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-κB signaling pathway in hepatocellular carcinoma.P18 peptide, a functional fragment of pigment epithelial-derived factor, inhibits angiogenesis in hepatocellular carcinoma via modulating VEGF/VEGFR2 signalling pathway.MiR-93-5p enhances growth and angiogenesis capacity of HUVECs by down-regulating EPLIN.
P2860
Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Anti-angiogenesis in hepatocel ...... dence and future perspectives.
@en
Anti-angiogenesis in hepatocel ...... dence and future perspectives.
@nl
type
label
Anti-angiogenesis in hepatocel ...... dence and future perspectives.
@en
Anti-angiogenesis in hepatocel ...... dence and future perspectives.
@nl
prefLabel
Anti-angiogenesis in hepatocel ...... dence and future perspectives.
@en
Anti-angiogenesis in hepatocel ...... dence and future perspectives.
@nl
P2860
P356
P1476
Anti-angiogenesis in hepatocel ...... dence and future perspectives.
@en
P2093
Joerg Trojan
Martin-Walter Welker
P2860
P304
P356
10.3748/WJG.V17.I26.3075
P407
P577
2011-07-01T00:00:00Z